APVO
HEALTHCAREAptevo Therapeutics Inc
$4.94-0.41 (-7.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving APVO Today?
No stock-specific AI insight has been generated for APVO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.80$136.80
$4.94
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-87.27
Dividend Yield—
Dividend / Share—
ROE-2.3%
Profit Margin—
Debt / Equity—
Trading
Volume462K
Avg Volume (10D)—
Shares Outstanding1.2M
APVO News
20 articles- Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionYahoo Finance·May 6, 2026
- Aptevo Therapeutics (APVO) Upgraded to Buy: Here's WhyYahoo Finance·Apr 10, 2026
- Aptevo to Participate in March 2026 ConferencesYahoo Finance·Mar 19, 2026
- Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%Yahoo Finance·Mar 10, 2026
- Aptevo Announces Executive Leadership Transitions to Support Next Phase of GrowthYahoo Finance·Feb 3, 2026
- Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic OptionalityYahoo Finance·Jan 9, 2026
- Sector Update: Health Care Stocks Edge Higher Late AfternoonYahoo Finance·Dec 26, 2025
- Aptevo Therapeutics Announces 1-for-18 Reverse Stock SplitYahoo Finance·Dec 26, 2025
- Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025Yahoo Finance·Dec 9, 2025
- Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowYahoo Finance·Nov 19, 2025
- Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid TumorsYahoo Finance·Nov 10, 2025
- Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business UpdateYahoo Finance·Nov 6, 2025
- Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth QuarterYahoo Finance·Oct 8, 2025
- Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index ReboundsYahoo Finance·Sep 18, 2025
- Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AMLYahoo Finance·Sep 16, 2025
- Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Sep 5, 2025
- Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five MoleculesYahoo Finance·Sep 4, 2025
- Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate CancerYahoo Finance·Aug 13, 2025
- Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business UpdateYahoo Finance·Aug 11, 2025
- Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Aug 8, 2025
All 20 articles loaded
Price Data
Open$4.55
Previous Close$5.35
Day High$5.02
Day Low$4.25
52 Week High$136.80
52 Week Low$3.80
52-Week Range
$3.80$136.80
$4.94
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-87.27
Dividend Yield—
Dividend / Share—
ROE-2.3%
Profit Margin—
Debt / Equity—
Trading
Volume462K
Avg Volume (10D)—
Shares Outstanding1.2M
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—